3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Other hematologic neoplasm
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Hepatocellular
4
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lymphoproliferative Disorders
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Mouth Neoplasms
1
Melanoma
1
Lymphoid Interstitial Pneumonia
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Hematologic Neoplasms
1
Fallopian Tube Neoplasms
1
Extensive Stage Lung Small Cell Carcinoma
1
Endometrial Neoplasms
1
Carcinoma
1
Advanced Solid Tumor
1
Interventions
entrectinib
2
atezolizumab
2
alectinib
2
trametinib
1
pertuzumab
1
dabrafenib
1
cobimetinib
1
capmatinib
1
Vemurafenib
1
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Lymphoproliferative Disorders
×
atezolizumab
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05770102
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled